Abstract：The research of chimeric antigen receptor modification T cells (CAR-T) is a hotspot in immunotherapy in recent years, which has achieved remarkable clinical efficacy in the treatment of hematological diseases. At present, CAR-T has also made great progress in the treatment of prostate cancer (PCa). CAR-T therapy targeting prostate-specific membrane antigen (PSMA) and prostate-stem cell antigen (PSCA) has made rapid progresses, which can significantly inhibit tumor cell growth and delay disease progression in a certain extent. This article reviewed the recent clinical research progress of prostate cancer associated antigen (TAA) in the treatment of prostate cancer with CAR-T, and briefly discussed the challenges of CAR-T in the treatment of prostate cancer for better clinical application.